Compare · COCH vs STE
COCH vs STE
Side-by-side comparison of Envoy Medical Inc. (COCH) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COCH and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $20.50B, about 404.6x COCH ($50.7M).
- Over the past year, COCH is down 55.8% and STE is down 11.9% - STE leads by 43.8 points.
- STE has been more active in the news (39 items in the past 4 weeks vs 5 for COCH).
- STE has more recent analyst coverage (16 ratings vs 2 for COCH).
- Company
- Envoy Medical Inc.
- STERIS plc (Ireland)
- Price
- $0.63-2.23%
- $213.79+1.79%
- Market cap
- $50.7M
- $20.50B
- 1M return
- -0.94%
- +3.12%
- 1Y return
- -55.78%
- -11.93%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 5
- 39
- Recent ratings
- 2
- 16
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest COCH
- Chief Executive Officer Lucas Brent T. was granted 32,856 shares, increasing direct ownership by 11% to 329,946 units (SEC Form 4)
- Envoy Medical to Present at Planet MicroCap Conference Las Vegas on June 16th-18th
- Envoy Medical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Envoy Medical Announces New Patents Expanding Intellectual Property Portfolio in Fully Implanted Hearing Technology
- Envoy Medical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form SCHEDULE 13G filed by Envoy Medical Inc.
- SEC Form SCHEDULE 13G filed by Envoy Medical Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Envoy Medical Inc.
- SEC Form 10-Q filed by Envoy Medical Inc.
- Envoy Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
Latest STE
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 401 units of Ordinary Shares, decreasing direct ownership by 1% to 36,678 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 65 units of Ordinary Shares, decreasing direct ownership by 1% to 6,194 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 195 units of Ordinary Shares, decreasing direct ownership by 2% to 12,257 units (SEC Form 4)
- SVP & GM, AST Kohler Kenneth E covered exercise/tax liability with 150 units of Ordinary Shares, decreasing direct ownership by 1% to 11,332 units (SEC Form 4)
- SVP & Chief HRO Fraser Mary Clare covered exercise/tax liability with 600 units of Ordinary Shares, decreasing direct ownership by 4% to 13,716 units (SEC Form 4)
- President and CEO Carestio Daniel A covered exercise/tax liability with 1,889 units of Ordinary Shares and sold $946,799 worth of Ordinary Shares (4,428 units at $213.82), decreasing direct ownership by 9% to 63,647 units (SEC Form 4)
- Sr. Vice Pres., CFO Burton Karen L covered exercise/tax liability with 90 units of Ordinary Shares, decreasing direct ownership by 0.68% to 13,184 units (SEC Form 4)
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 365 units of Ordinary Shares, decreasing direct ownership by 0.97% to 37,079 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 64 units of Ordinary Shares, decreasing direct ownership by 1% to 6,259 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 239 units of Ordinary Shares, decreasing direct ownership by 2% to 12,452 units (SEC Form 4)